How Effective Is Dose-Intensive/Myeloablative Therapy Against Ewing’s Sarcoma/Primitive Neuroectodermal Tumor Metastatic to Bone or Bone Marrow? The Memorial Sloan-Kettering Experience and a Literature Review

American Society of Clinical Oncology (ASCO) - Tập 19 Số 3 - Trang 870-880 - 2001
Brian H. Kushner1, Paul A. Meyers1
1From the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Tóm tắt

PURPOSE: Attempts to improve outcomes of patients with Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) metastatic to bone/bone marrow (BM) have focused on chemotherapy dose intensification strategies. We now present results achieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as reported in the literature. PATIENTS AND METHODS: Twenty-one unselected MSKCC patients with newly diagnosed ES/PNET metastatic to bone/BM received the “P6” protocol which includes cycles of cyclophosphamide (4.2 g/m2)/doxorubicin (75 mg/m2)/vincristine and cycles of ifosfamide (9 g/m2)/etoposide (500 mg/m2). Patients in complete/very good partial remission (CR/VGPR) after P6 received myeloablative therapy with either total-body irradiation (TBI) (hyperfractionated 15 Gy)/melphalan (180 mg/m2) or thiotepa (900 mg/m2)/carboplatin (1,500 mg/m2). We reviewed the literature. RESULTS: Only one MSKCC patient became a long-term event-free survivor; all but one relapse was in a distant site. Initial responses to P6 were CR/VGPR in 19 patients, but eight of them plus two others developed PD while receiving or shortly after completing P6. Eight patients were treated with TBI/melphalan: four relapsed 2 to 7 months after transplantation; two died early of toxicity; one died of pulmonary failure 17 months after transplantation (no evidence of ES/PNET); and one remains in CR at more than 7 years. The three patients treated with thiotepa/carboplatin relapsed 3 to 4 months after transplantation. All reports on large series of unselected patients with ES/PNET metastatic to bone/BM showed similarly unsatisfactory results. Poor outcome was seen with use of active agents for ES/PNET–cyclophosphamide, ifosfamide, doxorubicin, dactinomycin, vincristine, etoposide - at standard dosages for prolonged periods of time and at higher dosages in intensive regimens for short or prolonged periods of time. No improvements in event-free survival rates occurred with successive cooperative group or large single-institutional studies that used increasingly aggressive chemotherapeutic approaches. Inclusion of ifosfamide with or without etoposide made no difference nor did consolidation of remission with myeloablative chemoradiotherapy. Secondary leukemia emerged as a major risk with dose-intensive regimens. CONCLUSION: The MSKCC experience and findings reported in the literature suggest that dose-intensive use of the chemotherapy agents with established activity against ES/PNET is reaching its efficacy and toxicity limits. A major impact on prognosis awaits the development of entirely novel therapies.

Từ khóa


Tài liệu tham khảo

10.1016/S0031-3955(05)70541-1

10.1200/JCO.1995.13.11.2796

10.1200/JCO.1989.7.11.1748

10.1200/JCO.1987.5.11.1752

10.1200/JCO.1988.6.3.484

10.1016/0360-3016(91)90047-8

10.1200/JCO.1993.11.10.1911

10.1002/(SICI)1097-0142(19960815)78:4<901::AID-CNCR30>3.0.CO;2-X

10.1002/1097-0142(19900901)66:5<887::AID-CNCR2820660513>3.0.CO;2-R

10.1016/S0959-8049(97)00043-9

10.1200/JCO.1998.16.11.3628

10.1200/JCO.1997.15.7.2611

10.1200/JCO.1987.5.8.1199

10.1200/JCO.1992.10.11.1737

10.1002/(SICI)1096-911X(199603)26:3<180::AID-MPO6>3.0.CO;2-G

10.1097/00043426-199801000-00009

10.1200/JCO.1999.17.1.180

10.1055/s-2008-1033717

10.1200/JCO.1998.16.9.3044

10.1023/A:1008208511815

10.1023/A:1008264902857

Michon J, Oberlin O, Demeocq F, et al: Poor results in metastatic Ewing sarcomas (ES) treated according to the scheme of the Saint Jude 1978-1985 study: A study of the French Society of Pediatric Oncology. Med Pediatr Oncol 21: 572,1993 (abstr)

Miser JS, Krailo M, Meyers P, et al: Metastatic Ewing’s sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: Failure of new regimens to improve outcome. Proc Am Soc Clin Oncol 15: 467,1996 (abstr)

Koscielniak E, Harms D, Jürgens H, et al: Malignant peripheral neuroectodermal tumors (MPNT) and extraosseous Ewing sarcoma (EES) in childhood and adolescent: Results of the German Cooperative Soft Tissue Sarcoma Studies CWS-81 +86. Med Pediatr Oncol 27: 265,1996 (abstr)

Meyers P, Nachman J, Krailo M, et al: Induction chemotherapy (CT) followed by melphalan/etoposide/total body irradiation (MEL/E/TBI) and peripheral blood stem cell (PBSC) support for patients (pts) with newly diagnosed high-risk Ewing’s sarcoma (ES). Proc Am Soc Clin Oncol 19: 581a,2000 (abstr)

10.1016/0360-3016(88)90346-X

10.1016/0360-3016(83)90367-X

Miser J, Krailo M, Smith M, et al: Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing’s sarcoma. Proc Am Soc Clin Oncol 16: 518a,1997 (abstr)

10.3109/08880019409141808

10.1002/(SICI)1097-0142(19970801)80:3<489::AID-CNCR17>3.0.CO;2-T

10.1002/(SICI)1096-911X(200001)34:1<29::AID-MPO6>3.0.CO;2-7

Donaldson S, Shuster J, Andreozzi C, et al: The Pediatric Oncology Group (POG) experience in Ewings sarcoma of bone. Med Pediatr Oncol 17: 283,1989 (abstr)

10.1002/(SICI)1096-911X(199709)29:3<190::AID-MPO5>3.0.CO;2-8

10.1002/1097-0142(19880115)61:2<349::AID-CNCR2820610226>3.0.CO;2-0

Ladenstein R, Lasset C, Pinkerton R, et al: Impact of megatherapy in children with high-risk Ewing’s tumors in complete remission: A report from the EBMT Solid Tumor Registry. Bone Marrow Transplant 15: 697,1995-705,

Ladenstein R, Hartman O, Pinkerton R, et al: A multivariate and matched pair analysis on high-risk Ewing tumor (ET) patients treated with megatherapy (MGT) and stem cell reinfusion (SCR) in Europe. Proc Am Soc Clin Oncol 18: 2144,1999 (abstr)

Landenstein R, Peters C, Zoubek A, et al: The role of megatherapy (MGT) followed by stem cell rescue (SCR) in high risk Ewing tumors (ET). Med Pediatr Oncol 27: 237,1996 (abstr)

Hartmann O, Oberlin O, Beaujean F, et al: Place de la chimiothérapie à hautes doses suivie d’autogreffe médullaire dans le traitement des sarcomes d’Ewing métastatiques de l’enfant. Bull Cancer 77: 181,1990-187,

Emminger W, Emminger-Schmidmeier W, Peters C, et al: Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity? Bone Marrow Transplant 8: 119,1991-123,

10.3109/08880019109033423

10.1200/JCO.1993.11.8.1482

10.1002/(SICI)1096-911X(200005)34:5<328::AID-MPO3>3.0.CO;2-4

10.1038/sj.bmt.1701950

10.1038/sj.bmt.1700992

10.1136/adc.70.3.237

10.1038/sj.bmt.1701189

10.1200/JCO.1998.16.3.937

10.1200/JCO.1986.4.12.1804

Michon J, Hartmann O, Demeocq F, et al: Consolidation with busulfan and melphalan followed by blood progenitor cell (BPC) graft in children and young adults with high risk Ewing sarcoma: A report of the French Society of Pediatric Oncology (SFOP). Proc Am Soc Clin Oncol 13: 1415,1994 (abstr)

Valteau-Couanet D, Benhamou E, Oberlin O, et al: Consolidation with busulfan and melphalan followed by hematopoietic stem-cell transplantation (SCT) in children with poor risk prognosis Ewing’s sarcoma. Med Pediatr Oncol 25: 312,1995 (abstr)

Spitzer TR, Cirenza E, McAfee S, et al: Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 15: 537,1995-542,

Stewart DA, Gyonyor E, Paterson AHG, et al: High-dose melphalan ± total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing’s sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplant 18: 315,1996-318,

10.1038/sj.bmt.1701014

10.1016/S0360-3016(99)00063-2

10.1200/JCO.1998.16.9.3016

Cornbleet M, Corringham HG, Prentice HG, et al: Treatment of Ewing’s sarcoma with high-dose melphalan and autologous bone marrow rescue. Cancer Treat Rep 63: 241,1981-244,

Graham-Pole J, Lazarus H, Herzig R, et al: High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing’s sarcoma. Am J Pediatr Hematol Oncol 6: 17,1984-26,

10.3109/08880018509141221

Burdach S, Nurnberger W, Laws HJ, et al: Myeloablative therapy, stem cell rescue and gene transfer in advanced Ewing tumors. Bone Marrow Transplant 18: S67,1996-S68, (suppl 1, abstr)

10.3109/07357908909041371

Merino M, Navid F, Christensen B, et al: Immunomagnetic purging of Ewing’s sarcoma from blood: Quantitation by real-time PCR. Proc Am Soc Clin Oncol 19: 593a,2000 (abstr)

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 19 Số 3

870-880

Thông tin tác giả